Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Signal ; 64: 109410, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31487531

ABSTRACT

Short chain fatty acids (SCFAs) are produced by commensal bacteria in the gut and are known to reduce inflammation through transcriptional inhibition of cytokines and inflammatory proteins such as cyclooxygenase-2 (COX-2). Butyrate is a SCFA that was reported to alter the mRNA stability of inflammatory genes by increasiing the expression of the RNA binding protein (RBP) Tristetraprolin (TTP). We have hypothesized that butyrate may regulate gene expression post-transcriptionally through global effects on the expression or cytoplasmic translocation of RBPs. Using bioinformatics analyses of publicly available microarray data as well as colon cancer cell lines treated with sodium butyrate, we have observed that butyrate treatment led to a general reduction in expression of several (but not all) RBPs and inhibition in the cytosolic translocation of HuR, a well-known stabilizing RBP. This was reflected in reduced NanoLuc reporter activity of several different AU-rich element (ARE) sequences in the presence of butyrate; this suppression was retained even when HuR was overexpressed. Mechanistically, we have shown that reduced activity of HuR was related to decreased phosphorylation of p38 and MK2 and enhanced phosphorylation of Chk2. As a proof of concept, we show butyrate-mediated inhibition in binding of HuR to the 3'UTR of COX-2 mRNA resulting in reduced mRNA and protein levels of the inflammatory gene. Overall, our data suggest that butyrate can reduce the expression of inflammatory genes not only by transcriptional regulation, but also by post-transcriptional regulation via inhibition of mRNA stabilizing proteins.


Subject(s)
Butyrates/pharmacology , Gene Expression Regulation/drug effects , Inflammation/genetics , RNA-Binding Proteins/genetics , Caco-2 Cells , Cyclooxygenase 2/metabolism , ELAV-Like Protein 1/genetics , HCT116 Cells , HT29 Cells , Humans , RNA Stability/drug effects , RNA, Messenger/metabolism , Transcription, Genetic/drug effects
2.
Nutr Cancer ; 68(3): 495-506, 2016.
Article in English | MEDLINE | ID: mdl-27093594

ABSTRACT

We have previously shown that ethanolic extract from bark (EEB) of Salix aegyptiaca (Musk Willow) can inhibit proliferation and motility and induce apoptosis in colon cancer cells. Tandem mass spectrometry revealed EEB to be rich in catechin, catechol, and salicin. The present study investigated the chemopreventive effect of HPLC-fingerprinted EEB on 1,2-dimethylhydrazine (DMH)-induced aberrant crypt foci (ACF) formation in mice. DMH (20 mg/kg body weight) was weekly injected subcutaneously to mice for the first 2 weeks. EEB (100 and 400 mg/kg body weight) was provided orally from the 7th to 14th week, after which colon tissues were evaluated histologically and biochemically. DMH treatment induced high number of ACF; EEB significantly reduced the number and multiplicity of ACF, along with a restoration in goblet cells and mucin accumulation. EEB supplementation improved the markers of inflammation (myeloperoxidase and neutrophil infiltration) and oxidative stress. More importantly, EEB amplified apoptosis of neoplastic cells in the colon mucosa of DMH-treated mice. It also lowered levels of markers for early transformation events such as EGFR, nuclear ß-catenin, and COX-2 in colon cancer cell lines HT-29 and HCT-116. The innocuity of EEB (up to 1600 mg/kg) to mice reinforces its potential as a chemopreventive agent.


Subject(s)
1,2-Dimethylhydrazine/toxicity , Aberrant Crypt Foci/drug therapy , Anticarcinogenic Agents/pharmacology , Colonic Neoplasms/prevention & control , Plant Extracts/pharmacology , Salix/chemistry , Aberrant Crypt Foci/chemically induced , Aberrant Crypt Foci/pathology , Animals , Anticarcinogenic Agents/chemistry , Carcinogens/toxicity , Chromatography, High Pressure Liquid , Colonic Neoplasms/chemically induced , Colonic Neoplasms/pathology , Ethanol/chemistry , HCT116 Cells/drug effects , Humans , Inhibitory Concentration 50 , Male , Mice , Oxidative Stress/drug effects , Plant Bark/chemistry , Plant Extracts/chemistry
3.
Arch Biochem Biophys ; 596: 84-98, 2016 04 15.
Article in English | MEDLINE | ID: mdl-26946942

ABSTRACT

Quercetin (Qc) shows strong antitumor effects but has limited clinical application due to poor water solubility and bioavailability. In a screening of novel semi-synthetic derivatives of Qc, 3,7-dihydroxy-2-[4-(2-chloro-1,4-naphthoquinone-3-yloxy)-3-hydroxyphenyl]-5-hydroxychromen-4-one (CHNQ) could ameliorate acetic acid induced acute colitis in vivo more efficiently than Qc. Since inflammation contributes to colorectal cancer (CRC), we have hypothesized that CHNQ may have anti-cancer effects. Using CRC cell lines HCT-116 and HT-29, we report that CHNQ was three-fold more cytotoxic than Qc along with a robust induction of apoptosis. As expected from naphthoquinones such as CHNQ, a strong induction of oxidative stress was observed. This was accompanied by reactive oxygen species (ROS) induced autophagy marked by a dramatic increase in the lipidation of LC3, decreased activation of Akt/PKB, acidic vesicle accumulation and puncta formation in HCT-116 cells treated with CHNQ. Interestingly, an incomplete autophagy was observed in HT-29 cells where CHNQ treatment led to LC3 lipidation, but not the formation of acidic vacuoles. CHNQ-induced cytotoxicity, ROS formation and autophagy were also detected in vivo in Saccharomyces cerevisiae strain RDKY3615 (WinstonS288C background). Overall, we propose that CHNQ can induce cancer cell death through the induction of oxidative stress, and may be examined further as a potential chemotherapeutic drug.


Subject(s)
Autophagy/drug effects , Naphthoquinones , Oxidative Stress/drug effects , Quercetin , Saccharomyces cerevisiae/metabolism , Apoptosis/drug effects , Cell Line , Humans , Microtubule-Associated Proteins/metabolism , Naphthoquinones/chemistry , Naphthoquinones/pharmacology , Proto-Oncogene Proteins c-akt/metabolism , Quercetin/chemistry , Quercetin/pharmacology , Reactive Oxygen Species/metabolism , Saccharomyces cerevisiae Proteins/metabolism
4.
Nutr Cancer ; 66(6): 999-1008, 2014.
Article in English | MEDLINE | ID: mdl-25175673

ABSTRACT

Willow bark extracts have been used for centuries as a natural pain killer. Recently their potential as anticancer agents has been reported. We have shown the high antioxidant activity, phenolic and flavonoid content in the ethanolic extract of bark (EEB) from Salix aegyptiaca, a species endogenous to the Middle East. We have also reported that incubation with EEB resulted in a reduction in cell proliferation through the induction of apoptosis and cell cycle arrest via the inhibition of phosphatidyl inositol 3-kinase/Protein kinase B and mitogen activated protein kinases signaling pathways as strongly as commercial inhibitors. The current study demonstrates the robust inhibition of anchorage-independent growth, motility, migration, and adhesion of colon cancer cell lines HCT-116 and HT-29 by EEB. These in vitro functional changes were accompanied by a restoration of E-cadherin expression, a reduction in EGFR, SNAI1, SNAI2, and Twist1 and the matrix metalloproteases MMP9 and MMP2. Many of these proteins are involved in the process of epithelial to mesenchymal transition, which is considered as a critical step in the progression of noninvasive tumor cells into malignant, metastatic carcinomas. We therefore propose that EEB from Salix aegyptiaca is a potent nutraceutical causing cancer chemoprevention by inhibiting epithelial to mesenchymal transition and can be consumed for its health promoting effects.


Subject(s)
Colonic Neoplasms/pathology , Epithelial-Mesenchymal Transition/drug effects , Plant Bark/chemistry , Plant Extracts/pharmacology , Salix/chemistry , Apoptosis/drug effects , Cadherins/genetics , Cadherins/metabolism , Cell Adhesion/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation/drug effects , ErbB Receptors/genetics , ErbB Receptors/metabolism , HCT116 Cells , HT29 Cells , Humans , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Phytochemicals/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Snail Family Transcription Factors , Transcription Factors/genetics , Transcription Factors/metabolism , Twist-Related Protein 1/genetics , Twist-Related Protein 1/metabolism
5.
Nutr Cancer ; 65(7): 1045-58, 2013.
Article in English | MEDLINE | ID: mdl-24168160

ABSTRACT

The bark from Salix species of plants has been traditionally consumed for its antiinflammatory properties. Because inflammation frequently accompanies the progress of colorectal cancer (CRC), we have evaluated the anticancer properties of the ethanolic extract from the bark (EEB) of S. aegyptiaca, a Salix species endogenous to the Middle East, using HCT-116 and HT29 CRC cell lines. Fresh bark from S. aegyptiaca was extracted with ethanol, fractionated by solvent-solvent partitioning and the fractions were analyzed by tandem mass spectrometry. Catechin, catechol, and salicin were the most abundant constituents of the extract. Interestingly, EEB showed the highest anticancer effect in the colon cancer cells followed by its fractions in ethyl acetate and water, with catechin, catechol, and salicin showing the least efficacy. EEB could strongly reduce the proliferation of the cancer cells, but not of CCD-18Co, normal colon fibroblast cell line. Accompanying this was cell cycle arrest at G1/S independent of DNA damage in the cancer cells, induction of apoptosis through a p53 dependent pathway and an inhibition of PI3K/Akt and MAP Kinase pathways at levels comparable to known commercial inhibitors. We propose that the combination of the polyphenols and flavonoids in EEB contributes toward its potent anticarcinogenic effects. [Supplementary materials are available for this article. Go to the publisher's online edition of Nutrition and Cancer for the following free supplemental resource(s): Supplementary Figure 1 and Supplementary Figure 2.].


Subject(s)
Anticarcinogenic Agents/pharmacology , Colonic Neoplasms/metabolism , Plant Extracts/pharmacology , Salix/chemistry , Signal Transduction/drug effects , Apoptosis/drug effects , Caspase 3/genetics , Caspase 3/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Flavonoids/pharmacology , HT29 Cells , Humans , Mitogen-Activated Protein Kinases/genetics , Mitogen-Activated Protein Kinases/metabolism , Oxidative Stress/drug effects , Phosphatidylinositol 3-Kinases/genetics , Phosphatidylinositol 3-Kinases/metabolism , Plant Bark/chemistry , Polyphenols/pharmacology , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism
6.
Iran J Pharm Res ; 9(3): 293-6, 2010.
Article in English | MEDLINE | ID: mdl-24363740

ABSTRACT

This study was designed to examine the in vitro antioxidant activities and total phenolic contents of the methanolic extracts from male inflorescence of Salix aegyptiaca L. grown in Iran. The methanolic extract (ME) and its three fractions including water (WF), butanol (BF) and chloroform (CF) were prepared and then their antioxidant activities, as well as total phenolic contents, were evaluated by 2, 2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging assay and the Folin-Ciocalteu method, respectively. Among the different fractions of methanol extract, BF indicated the most antioxidant activity with an IC50 value of 27.7 µg/mL and total phenols of 313.8 ppm, which is comparable with the synthetic antioxidant BHT (IC50 = 26.5µg/mL). The antioxidant activities of the other fractions decreased in the order of ME >WF > CF. The potent antioxidant activity of S. aegyptiaca supported its possible use as a natural antioxidant in food industries and other pharmaceutical preparations.

SELECTION OF CITATIONS
SEARCH DETAIL
...